Evaluating Therapeutic Options in Chronic Lymphocytic Leukemia

With regard to cytogenetic testing, molecular testing, and imaging, Nicole Lamanna, M.D., outlines what testing should be completed alongside a diagnosis of chronic lymphocytic leukemia (CLL).

Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).

The optimal length of time to wait to initiate treatment for patients with chronic lymphocytic leukemia (CLL), as well as the length of time to remain on treatment, are described by Nicole Lamanna, M.D.

In the setting of relapsed chronic lymphocytic leukemia, Nicole Lamanna, M.D., considers the patient and disease factors that affect her selection of therapy.
 

In the context of therapeutic management of chronic lymphocytic leukemia (CLL), Nicole Lamanna, M.D., offers advice regarding lifestyle modifications that may improve outcomes for patients.

Nicole Lamanna, M.D., provides insight on how the management of chronic lymphocytic leukemia (CLL) might progress as new therapeutic agents are introduced or matched together.

Factors that help clinicians distinguish chronic lymphocytic leukemia from other B-cell lymphomas and a testimony from Danise Hoover, a patient diagnosed with CLL.

The rationale for a watch and wait approach versus treatment initiation in patients with chronic lymphocytic leukemia.

Typical signs and symptoms that may indicate it is time to initiate therapy in a patient with chronic lymphocytic leukemia.

Tests used to help clinicians decide on an effective treatment approach for patients with chronic lymphocytic leukemia.

Danise Hoover, a patient with chronic lymphocytic leukemia, recalls her experience with first-line chemoimmunotherapy. Expert Nicole Lamanna, M.D., provides an overview of regimens typically used in patients such as Danise.

An overview of the different levels of clinical trials and their significance in providing patients with chronic lymphocytic leukemia with alternatives for treatment.
 

Patient and clinician insight on the process involved in the enrollment in a clinical trial for the treatment of chronic lymphocytic leukemia and typical patient factors that help determine one’s eligibility.

Danise Hoover recalls her experience receiving venetoclax, an oral targeted agent. Nicole Lamanna, M.D., discusses the rationale for Danise’s treatment recommendation and remarks on the benefits of treating patients with chronic lymphocytic leukemia with venetoclax.
 

Patient and clinician considerations for managing adverse events throughout treatment with novel targeted agents such as venetoclax as therapy for chronic lymphocytic leukemia.
 

Recommendations for patients and loved ones impacted by a diagnosis of chronic lymphocytic leukemia on locating helpful resources and establishing a strong network of support.
 

Nicole Lamanna, M.D., and patient Danise Hoover react to treatment planning for chronic lymphocytic leukemia in the era of novel targeted agents.